CoChat

Effects of Inulin-Based Prebiotics Alone or in Combination with Probiotics on Human Gut Microbiota and Markers of Immune System: A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Subjects

Open access
De Giani, Alessandra, Sandionigi, Anna, Zampolli, Jessica, Michelotti, Angela, Tursi, Francesco, Labra, Massimo, Di Gennaro, Patrizia · 2022 · Microorganisms

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index; 10 of the 68 sources its claims cite were checked for support.

Abstract

The gut microbiota is implicated in diverse interactions affecting human health. The present study reports a randomized, double-blind, placebo-controlled clinical study conducted by administering a new synbiotic formulation composed of two Lactobacillus strains (L. plantarum and L. acidophilus) and one Bifidobacterium strain (B. animalis subsp. lactis) and two types of fructans (fructo-oligosaccharides with a degree of polymerization of 3–5 and inulin-type fructans with 10 DP). The effects of this synbiotic were evaluated on healthy subjects for 28 days and the maintenance of its efficacy was evaluated at the end of a follow-up period of 28 days. The synbiotic treatment contributes to higher biodiversity of the gut microbiota, increasing the community richness with respect to the group with the prebiotics alone and the placebo group. Its positive effect is also reflected in the variation of microbial community structure favoring the beneficial short-chain fatty acids bacterial producers. The amelioration of the health status of the subjects was also established by the reduction of common infectious disease symptom incidence, the stimulation of the gut immune system showing a noteworthy variation of fecal β-defensin2 and calprotectin levels, and the modulation of the response of the respiratory tract’s immune system by salivary IgA as well as total antioxidant capacity biomarkers.

Overview

CoChat Summary

## TL;DR

This randomized, double-blind, placebo-controlled study in 75 healthy elderly subjects found that a synbiotic containing two Lactobacillus strains, one Bifidobacterium strain, and inulin/FOS improved gut microbiota diversity and several immune-related markers more than prebiotics alone or placebo. The synbiotic also reduced common infectious disease (CID) incidence and lowered fecal calprotectin while increasing fecal β-defensin2.

## Key findings

  • The study enrolled 75 healthy elderly Caucasian men and women, randomized 1:1:1 to prebiotic, synbiotic, or placebo for 28 days, with 28 days of follow-up.
  • Gut microbiome alpha diversity (Faith PD) increased significantly from T0 to T56 in both the synbiotic group (p = 0.045) and the prebiotic group (p = 0.02); after T0–T28, both A vs D and B vs D differed significantly (A vs D U = 149, p = 0.02; B vs D U = 301, p = 0.04).
  • The synbiotic group had lower CID burden: 36% of subjects reported at least one CID episode during T0–T28 and 12% during T28–T56, versus 48%/20% in prebiotic and 56%/20% in placebo; over T0–T56, 48% of synbiotic subjects had at least one CID episode versus 68% prebiotic and 76% placebo.
  • Fecal calprotectin normalized in the synbiotic group from 88% of subjects at baseline to 96% at T28 and 100% at T56; fecal β-defensin2 increased by about 22% in the synbiotic group over T0–T56, while the prebiotic group showed a 25% increase at the first endpoint and salivary TAC increased significantly only with synbiotic at T0–T28 (p < 0.05).

## Methods

  • Randomized, double-blind, placebo-controlled clinical trial in 75 healthy elderly Caucasian subjects aged 60–80 years with BMI 18.5–24.99.
  • Three arms: prebiotic (50 mg FOS + 50 mg inulin), synbiotic (3 probiotic strains plus the same prebiotics), and placebo, taken once daily for 28 days, with assessments at T0, T28, and T56.
  • Main analyses included 16S rDNA V3–V4 sequencing, qPCR for probiotic strains, QIIME2/DADA2 community analysis, Faith PD, MAZ scoring, and nonparametric tests (Wilcoxon signed-rank, Mann-Whitney).

## Limitations

  • The paper states the study had a small number of subjects because eligible elderly participants without severe concurrent diseases were difficult to enroll.
  • It also states a limitation of using immune biomarkers without clinical outcomes, making minor immunomodulatory effects hard to interpret.
  • Evident from the text: the population was restricted to healthy elderly Caucasian subjects, so generalizability to other ages, ethnicities, or less healthy populations is not established.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/microorganisms10061256

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Study flow and schedule of assessment chart depicting the overall study design. The study corresponds to a randomized, double-blind, three-arm parallel-group, placebo-controlled. Levels of several immunological markers (fecal Calprotectin and ß-Defensin2; salivary IgA and total antioxidant capacity) and composition of intestinal microbiota (qPCR and NGS sequencing) were evaluated at three time-points during the study (baseline T0, at the end of the treatment period T28, and at the end of the follow-up T56).
Figure 1 Study flow and schedule of assessment chart depicting the overall study design. The study corresponds to a randomized, double-blind, three-arm parallel-group, placebo-controlled. Levels of several immunological markers (fecal Calprotectin and ß-Defensin2; salivary IgA and total antioxidant capacity) and composition of intestinal microbiota (qPCR and NGS sequencing) were evaluated at three time-points during the study (baseline T0, at the end of the treatment period T28, and at the end of the follow-up T56).CC BY · PubMed Central
Figure 2 Gut microbiota composition of all the subjects analyzed by 16S rDNA V3-V4 region amplification at the three time-points (T0, T28, and T56). The relative abundance of bacterial ASVs at phylum level in every subject belonging to Prebiotic (A), Synbiotic (B), or Placebo (D) groups is shown by taxa bar plots. Each subject is identified by a bar and the different colored boxes represent the taxa (the percentage of relative abundance) within the sample. The legend shows the taxa from the most abundant (left) to the less abundant (right).
Figure 2 Gut microbiota composition of all the subjects analyzed by 16S rDNA V3-V4 region amplification at the three time-points (T0, T28, and T56). The relative abundance of bacterial ASVs at phylum level in every subject belonging to Prebiotic (A), Synbiotic (B), or Placebo (D) groups is shown by taxa bar plots. Each subject is identified by a bar and the different colored boxes represent the taxa (the percentage of relative abundance) within the sample. The legend shows the taxa from the most abundant (left) to the less abundant (right).CC BY · PubMed Central
Figure 3 Venn diagram illustrating the percentage of Amplicon Sequence Variants (ASVs) that were shared or not shared by the gut microbiota of the three study-groups: Prebiotic (A), Synbiotic (B), or Placebo (D). Panel (a) represents the T28, and panel (b) represents the T56.
Figure 3 Venn diagram illustrating the percentage of Amplicon Sequence Variants (ASVs) that were shared or not shared by the gut microbiota of the three study-groups: Prebiotic (A), Synbiotic (B), or Placebo (D). Panel (a) represents the T28, and panel (b) represents the T56.CC BY · PubMed Central
Figure 4 Comparison of the variation of the gut microbiota biodiversity by Faith PD value between Prebiotic (A), Synbiotic (B), and Placebo (D) groups during the following intervals of the study: the first 28 days of administration (T0–T28) (a), during the 56 days of the study (T0–T56) (b), and during the follow-up period (T28–T56) (c). Statistical differences between treatment groups were calculated using Mann-Whitney test (* p-value < 0.05).
Figure 4 Comparison of the variation of the gut microbiota biodiversity by Faith PD value between Prebiotic (A), Synbiotic (B), and Placebo (D) groups during the following intervals of the study: the first 28 days of administration (T0–T28) (a), during the 56 days of the study (T0–T56) (b), and during the follow-up period (T28–T56) (c). Statistical differences between treatment groups were calculated using Mann-Whitney test (* p-value < 0.05).CC BY · PubMed Central
Figure 5 Volatility plot representing the trend of variation of the gut microbiota of the three treatment-groups. It represents the degree of change between selected time-points (T0, T28, and T56) and the resilience of the subject microbiota after the treatment with Prebiotics (A), Synbiotic (B), or Placebo (D). Thick curves are colored according to MAZ median-values, and the vertical bars represent error bars.
Figure 5 Volatility plot representing the trend of variation of the gut microbiota of the three treatment-groups. It represents the degree of change between selected time-points (T0, T28, and T56) and the resilience of the subject microbiota after the treatment with Prebiotics (A), Synbiotic (B), or Placebo (D). Thick curves are colored according to MAZ median-values, and the vertical bars represent error bars.CC BY · PubMed Central
Figure 6 Heat map of ASVs variation of gut microbiota of elderly subjects of each treatment-group over time. In the logarithmic scale, color intensity indicates the abundance of each ASV feature. On the bottom of the heat map, the ASVs that varied for the three treatment-groups (Prebiotic A group, Synbiotic B group, Placebo D group) during the three time-points (T0 baseline, T28 time-point corresponding to the end of the treatment period, T56 time-point corresponding to the end of the follow-up period). On the top, the dendrogram of similarity between all the samples is represented.
Figure 6 Heat map of ASVs variation of gut microbiota of elderly subjects of each treatment-group over time. In the logarithmic scale, color intensity indicates the abundance of each ASV feature. On the bottom of the heat map, the ASVs that varied for the three treatment-groups (Prebiotic A group, Synbiotic B group, Placebo D group) during the three time-points (T0 baseline, T28 time-point corresponding to the end of the treatment period, T56 time-point corresponding to the end of the follow-up period). On the top, the dendrogram of similarity between all the samples is represented.CC BY · PubMed Central
Figure 7 Heat map representing the significant biodiversity variation of ASVs assigned to the following bacterial genera Akkermansia, Bifidobacterium, Blautia, Faecalibacterium, Prevotella, Roseburia, and Ruminococcus for the three treatment-groups (Prebiotic A group, Synbiotic B group, and Placebo D group) during the three intervals of time-points (T0–T28 corresponding to the administration period, T0–T56 corresponding to 56 days of the study period, and T28–T56 corresponding to the follow-up period). Mann-Whitney test at two levels of significance was applied. The red squares depict a negative variation, the green ones depict a positive variation.
Figure 7 Heat map representing the significant biodiversity variation of ASVs assigned to the following bacterial genera Akkermansia, Bifidobacterium, Blautia, Faecalibacterium, Prevotella, Roseburia, and Ruminococcus for the three treatment-groups (Prebiotic A group, Synbiotic B group, and Placebo D group) during the three intervals of time-points (T0–T28 corresponding to the administration period, T0–T56 corresponding to 56 days of the study period, and T28–T56 corresponding to the follow-up period). Mann-Whitney test at two levels of significance was applied. The red squares depict a negative variation, the green ones depict a positive variation.CC BY · PubMed Central
Figure 8 Bar plot representing the cumulative variation numbers of ASVs corresponding to seven bacterial genera Akkermansia, Bifidobacterium, Blautia, Faecalibacterium, Prevotella, Roseburia, and Ruminococcus for each treatment-group (Prebiotic A group, Synbiotic B group, and Placebo D group) during the three intervals of time-points (T0–T28 corresponding to the administration period, T0–T56 corresponding to 56 days of the study period, and T28–T56 corresponding to the follow-up period). The red squares depict a negative variation, the green ones depict a positive variation.
Figure 8 Bar plot representing the cumulative variation numbers of ASVs corresponding to seven bacterial genera Akkermansia, Bifidobacterium, Blautia, Faecalibacterium, Prevotella, Roseburia, and Ruminococcus for each treatment-group (Prebiotic A group, Synbiotic B group, and Placebo D group) during the three intervals of time-points (T0–T28 corresponding to the administration period, T0–T56 corresponding to 56 days of the study period, and T28–T56 corresponding to the follow-up period). The red squares depict a negative variation, the green ones depict a positive variation.CC BY · PubMed Central
Figure 9 Quantification of cell numbers of L. plantarum (Panel (A)), L. acidophilus (Panel (B)), and B. animalis spp. lactis (Panel (C)) in fecal samples by species-specific qPCR at different time-points (T0 baseline, T28 time-point corresponding to the end of the treatment period, T56 time-point corresponding to the end of the follow-up period). Data are expressed as the mean values of CFU/mL per g of feces and error bars represent the SEM. The Wilcoxon rank-signed test was applied for the comparisons within each treatment group, highlighted in red, blue, and green color for Prebiotic (A), Synbiotic (B), and Placebo (D) groups, respectively. The Mann-Whitney test was applied for the comparisons between groups, reported in black color (* p-value < 0.05 and ** p-value < 0.01).
Figure 9 Quantification of cell numbers of L. plantarum (Panel (A)), L. acidophilus (Panel (B)), and B. animalis spp. lactis (Panel (C)) in fecal samples by species-specific qPCR at different time-points (T0 baseline, T28 time-point corresponding to the end of the treatment period, T56 time-point corresponding to the end of the follow-up period). Data are expressed as the mean values of CFU/mL per g of feces and error bars represent the SEM. The Wilcoxon rank-signed test was applied for the comparisons within each treatment group, highlighted in red, blue, and green color for Prebiotic (A), Synbiotic (B), and Placebo (D) groups, respectively. The Mann-Whitney test was applied for the comparisons between groups, reported in black color (* p-value < 0.05 and ** p-value < 0.01).CC BY · PubMed Central
Figure 10 Average number of days related to common infectious disease (CID) symptoms that affected the elderly subjects at the different intervals of the three time-points (total period T0–T56, treatment period T0–T28, and follow-up period T28–T56) for Prebiotic (A), Synbiotic (B), and Placebo (D) groups. Data are expressed as mean ± SEM. The Mann–Whitney test was applied (* p-value < 0.05 and ** p-value < 0.01).
Figure 10 Average number of days related to common infectious disease (CID) symptoms that affected the elderly subjects at the different intervals of the three time-points (total period T0–T56, treatment period T0–T28, and follow-up period T28–T56) for Prebiotic (A), Synbiotic (B), and Placebo (D) groups. Data are expressed as mean ± SEM. The Mann–Whitney test was applied (* p-value < 0.05 and ** p-value < 0.01).CC BY · PubMed Central
Figure 11 Percentage of subjects with levels of fecal calprotectin below the normal value of 45 µg/g. Levels were measured at T0 baseline, T28 time-point corresponding to the end of the treatment period, T56 time-point corresponding to the end of the follow-up period for Prebiotic (A), Synbiotic (B), and Placebo (D) groups.
Figure 11 Percentage of subjects with levels of fecal calprotectin below the normal value of 45 µg/g. Levels were measured at T0 baseline, T28 time-point corresponding to the end of the treatment period, T56 time-point corresponding to the end of the follow-up period for Prebiotic (A), Synbiotic (B), and Placebo (D) groups.CC BY · PubMed Central
Figure 12 Fecal β-Defensin2 levels measured at T0 baseline, T28 time-point corresponding to the end of the treatment period, T56 time-point corresponding to the end of the follow-up period for Prebiotic (A), Synbiotic (B), and Placebo (D) groups. Values are expressed as mean ± SEM. The Wilcoxon rank-signed test was applied for the comparisons within each treatment group, highlighted in red, blue, and green color for Prebiotic (A), Synbiotic (B), and Placebo (D) groups, respectively. The Mann–Whitney test was applied for the comparisons between groups, reported in black color (* p-value < 0.05).
Figure 12 Fecal β-Defensin2 levels measured at T0 baseline, T28 time-point corresponding to the end of the treatment period, T56 time-point corresponding to the end of the follow-up period for Prebiotic (A), Synbiotic (B), and Placebo (D) groups. Values are expressed as mean ± SEM. The Wilcoxon rank-signed test was applied for the comparisons within each treatment group, highlighted in red, blue, and green color for Prebiotic (A), Synbiotic (B), and Placebo (D) groups, respectively. The Mann–Whitney test was applied for the comparisons between groups, reported in black color (* p-value < 0.05).CC BY · PubMed Central
Figure 13 Salivary IgA levels measured at T0 baseline, T28 time-point corresponding to the end of the treatment period, T56 time-point corresponding to the end of the follow-up period for Prebiotic (A), Synbiotic (B), and Placebo (D) groups. Values are expressed as mean ± SEM. The Wilcoxon rank-signed test and the Mann–Whitney test were applied, and no significant differences were observed.
Figure 13 Salivary IgA levels measured at T0 baseline, T28 time-point corresponding to the end of the treatment period, T56 time-point corresponding to the end of the follow-up period for Prebiotic (A), Synbiotic (B), and Placebo (D) groups. Values are expressed as mean ± SEM. The Wilcoxon rank-signed test and the Mann–Whitney test were applied, and no significant differences were observed.CC BY · PubMed Central
Figure 14 Salivary total antioxidant capacity (TAC) measured by FRAP assay at T0 baseline, T28 time-point corresponding to the end of the treatment period, T56 time-point corresponding to the end of the follow-up period for Prebiotic (A), Synbiotic (B), and Placebo (D) groups. Values are represented as mean ± SEM. Statistical differences were calculated using Wilcoxon rank-signed test (* p-value < 0.05). The statistical comparison within the synbiotic treatment group is highlighted in blue.
Figure 14 Salivary total antioxidant capacity (TAC) measured by FRAP assay at T0 baseline, T28 time-point corresponding to the end of the treatment period, T56 time-point corresponding to the end of the follow-up period for Prebiotic (A), Synbiotic (B), and Placebo (D) groups. Values are represented as mean ± SEM. Statistical differences were calculated using Wilcoxon rank-signed test (* p-value < 0.05). The statistical comparison within the synbiotic treatment group is highlighted in blue.CC BY · PubMed Central

Verification

Claims the paper makes

7 Valid · 1 Not valid · 39 Not checked · 90 Own results and interpretations

55 more claims

Create a free account to see all 137 claims and to verify the 58 references still open.

See all claims — free account
  • Probably not a substantial claim. 43
  • It may state two separate claims as one. 50

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 60 references

Research works printed but not linked: 1

  1. Manfredi, E. (2015). Biological Sciences. [Ph.D. Thesis, University of Milano-Bicocca].

Cited by

See all 54

Metadata

Authors
De Giani, A., Sandionigi, A., Zampolli, J., Michelotti, A., Tursi, F., Labra, M., & Di Gennaro, P.
Affiliations
  • Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza Della Scienza 2, 20126 Milano, MI, Italy
  • University of Milano-Bicocca (IT)
  • Complife Italia S.r.l., Via Angelini 21, 27028 San Martino Siccomario, PV, Italy
Venue
Microorganisms
Publisher
MDPI AG
Published
2022-06-20
Volume
10
Issue
6
Pages
1256
ISSN
2076-2607 (ISSN-L)
OpenAlex
W4283263429
Cited by
46
References
60
Citations by year
2026: 12 · 2025: 16 · 2024: 9 · 2023: 6 · 2022: 3
FWCI
5.25
Type
journal article
Language
en
Open access
Locations
  • Microorganisms (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • BOA (University of Milano-Bicocca) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Natural Activities and Technologies Under Research for Healthy Aging (NATURHA) (138946)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Microbial Metabolites in Food Biotechnology
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
synbiotics, inulin-type fructans, fructooligosaccharides, Lactobacillus plantarum, Lactobacillus acidophilus, Bifidobacterium animalis subsp. lactis, gut microbiota, short-chain fatty acids, human beta-defensin 2, calprotectin, salivary IgA, lung immunity, antioxidant capacity, microbial diversity, healthy volunteers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Inulin-Based Prebiotics Alone or in Combination with Probiotics on Human Gut Microbiota and Markers of Immune System: A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Subjects. https://app.cochat.ai/papers/10.3390/microorganisms10061256
The paper
De Giani, A., Sandionigi, A., Zampolli, J., Michelotti, A., Tursi, F., Labra, M., & Di Gennaro, P. (2022). Effects of Inulin-Based Prebiotics Alone or in Combination with Probiotics on Human Gut Microbiota and Markers of Immune System: A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Subjects. Microorganisms. https://doi.org/10.3390/microorganisms10061256

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.